Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established high-risk factors

The variable outcome to standard immunochemotherapy for mantle cell lymphoma (MCL) patients is a clinical challenge. Established risk factors, including high MCL International Prognostic Index (MIPI), high proliferation (Ki-67), non-classic (blastoid/pleomorphic) morphology, and mutated TP53, only p...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerdtsson, Anna Sandström, de Matos Rodrigues, Joana, Eskelund, Christian Winther, Husby, Simon, Grønbæk, Kirsten, Räty, Riikka, Kolstad, Arne, Geisler, Christian, Porwit, Anna, Jerkeman, Mats, Ek, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Non-Hodgkin Lymphoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071121/
https://www.ncbi.nlm.nih.gov/pubmed/36519324
http://dx.doi.org/10.3324/haematol.2022.281420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071121/
https://www.ncbi.nlm.nih.gov/pubmed/36519324
http://dx.doi.org/10.3324/haematol.2022.281420

Ejemplares similares